Medical Devices; Exemptions From Premarket Notification: Class II Devices; Request for Comments
Published Date: 2/6/2026
Notice
Summary
The FDA is thinking about letting some medium-risk medical devices skip a step called premarket notification, which means faster and easier approval. They want to hear from the public by April 7, 2026, before making a final decision. This could save time and money for device makers and get helpful devices to patients quicker.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Listed Class II Devices May Be Exempt
FDA proposes that the class II device types listed in Table 1 and Table 2 would no longer require premarket notification under section 510(k) if the proposal is finalized. FDA says this final action "will decrease regulatory burdens on the medical device industry and will eliminate private costs and expenditures" because manufacturers "will no longer have to invest time and resources in 510(k) submissions" for exempt devices.
Exemptions Limited; Some Devices Still Need 510(k)
FDA proposes partial limitations so that only devices meeting specified conditions would be exempt; devices that fall outside those partial limitations would remain subject to 510(k). For example, a uterine tenaculum would be exempt only if it is a manual mechanical device, and powered uterine tenacula (such as vacuum-based devices) would still require premarket notification.
New Product Codes for Exempt Devices
If exemptions are finalized, FDA will assign new product codes to device types that become exempt so they can be identified separately from devices that remain subject to 510(k). Exempt and non-exempt devices within the same device type will therefore have different product codes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-02376 — Foreign-Trade Zone (FTZ) 110, Notification of Proposed Production Activity; Intel Foundry Corporation; (Semiconductor Products); Rio Rancho and Albuquerque, New Mexico
Intel Foundry Corporation wants to start making advanced semiconductor products at its Rio Rancho and Albuquerque, New Mexico sites under special Foreign-Trade Zone rules. This move lets them use certain imported materials duty-free, helping save money and speed up production. The government is reviewing this plan, which could boost local tech manufacturing soon.
Next: 2026-02378 — Indian Gaming; Approval by Operation of Law of the First Amendment to the Tribal-State Gaming Compact Between the State of California and the Sycuan Band of the Kumeyaay Nation
The first amendment to the gaming agreement between California and the Sycuan Band of the Kumeyaay Nation is now officially approved by law as of February 6, 2026. This means the tribe can continue running certain casino games under updated rules without delay. No extra money changes were announced, but the approval keeps the gaming partnership strong and on track.